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This year, the Albert Lasker Basic Medical Research Award will be shared by Douglas Coleman and
Jeffrey Friedman for their discovery of leptin, a hormone that regulates appetite and body weight.
By uncovering a critical physiologic system, their discovery markedly accelerated our capacity to
apply molecular and genetic techniques to understand obesity.Together, Douglas Coleman (left) and Jeffrey Friedman (right) discovered the hormone leptin,
which signals to the brain the state of energy stores in peripheral tissues.The discovery of leptin was a landmark
event in modern physiology. Leptin is
a hormone derived from fat that informs
the brain about the status of energy stores
in peripheral tissues, and its discovery
closed a physiologic feedback loop that
was long hypothesized to control normal
energy homeostasis. Now, the Albert
Lasker Basic Medical Research Award
is recognizing the researchers who
produced this breakthrough, Douglas
Coleman at The Jackson Laboratory
and Jeffrey Friedman at The Rockefeller
University and the Howard Hughes
Medical Institute.
Although the contributions of the two
awardees differed in approach and
occurred three decades apart, their joint
recognition reflects the essential contri-
butions that each researcher made to
this field-changing discovery. Doug Cole-
man is recognized for demonstrating that
a ‘‘satiety factor’’ circulating in the blood
stream was absent in a mutant mouse
strain (ob/ob) that is severely obese
and for correctly predicting that the hypo-
thalamus is the target of this factor.
Stimulated by Coleman’s results, Jeffrey
Friedman took up the ambitious goal of
cloning the genes mutated in the mouse
strain at a time when such a feat was
extremely difficult. He found that the ob
gene encodes a protein hormone that
reverses obesity and metabolic abnor-
malities in the ob/ob mice. These discov-
eries revised our understanding of inte-
grative metabolism and set the stage for
explosive and still accelerating research
efforts in numerous fields.
Background History
Sometimes in science, a single break-
through changes a field in such a dramaticway that newcomers to the field have diffi-
culty appreciating the ‘‘landscape’’ of the
research prior to the discovery. This is
surely the case for the field of energy
balance regulation before and after the
discovery of leptin. Even 30 years before
leptin’s discovery, a substantial body of
evidence suggested that energy intake
and expenditure were tightly regulated.
For example, when animals were forcibly
overfed (or starved) and then returned to
their original diets, they reliably and often
quite precisely returned to their initial
weights. Clearly, a physiologic homeo-
static system of some type was in play.
Furthermore, it was known that small
lesions in the hypothalamus caused eitherCellobesity or leanness in humans and mice
by disrupting food intake and possibly
energy expenditure. For some scientists,
these results suggested that regions
within the hypothalamus might be master
regulators of energy balance, integrating
signals from peripheral organs that reflect
the energy status of the organism and
then engaging pathways to adjust nutrient
intake and energy expenditure tomaintain
homeostasis.
Experimental support for this concept
emerged slowly. In 1959, the British phys-
iologist William Hervey published a
prescient study reporting the results
of surgically joining normal rats with
those given lesions in the ventromedial143, October 1, 2010 ª2010 Elsevier Inc. 9
hypothalamus (VMH), which were known
to cause obesity (Hervey, 1959). In these
‘‘parabiotic’’ experiments, Hervey con-
nected the rats through their subcuta-
neous tissues, permitting a low-rate
exchange of extracellular and blood-
borne elements from one animal to the
other. Although Hervey was not the first
researcher to employ this experimental
model, the surgical unions between these
particular rats generated a particularly
interesting result.
As expected, the rats with VMH lesions
becameobese. Surprisingly, however, the
normal rats ingested far less food than
usual and lost substantial weight when
they were joined to the obese rats. Based
on these results, Hervey postulated that
the VMH normally responds to a satiety
signal that regulates feeding. Without
a functional VMH, the rats could not
respond to this signal; they becameobese
and then overproduced the satiety signal,
which Hervey postulated was a peripheral
factor. Furthermore, Hervey surmised that
high levels of this signal crossed over into
the circulation of the normal rats, sup-
pressing their food intake and weight.
Remarkably, this hypothesis proved to
be correct. However, given the complexity
of the parabiotic model used in the study,
more pedestrian explanations might
easily have accounted for the decreased
food intake of the normal rats. Plus, identi-
fying a hypothesized hormone from an
unknown site was a daunting task, which
led many in the field to look elsewhere
for interesting experiments to pursue.
Despite much speculation and the
suggestive evidence from this study and
related approaches, no convincing proof
hademerged for theexistenceofaspecific
physiologic system that controls energy
intake, energy expenditure, and body
weight when Douglas Coleman began to
tackle the problem over the next decade.
Coleman Connects the Dots
Douglas Coleman obtained a doctorate in
biochemistry at the University of Wiscon-
sin and took his first position at The Jack-
son Laboratory in Bar Harbor, Maine in
1958, where he expected to remain for
only a couple of years to extend his under-
standing of genetics. Instead, he spent his
entire career at The Jackson Laboratory
until he retired in 1991. At the beginning,
his research focused on muscle disorders10 Cell 143, October 1, 2010 ª2010 Elsevierin mice. However, his most notable ac-
complishments occurred while studying
mice with genetic syndromes of obesity
and diabetes, and at the time, The Jack-
son Laboratory was fertile soil for sowing
such studies.
In 1949, an autosomal recessive
syndrome of severe obesity appeared
spontaneously in a colony of mice at The
Jackson Laboratory. The mutation map-
ped to chromosome 6 and was desig-
nated obese (ob). In 1966, Coleman and
his associates identified a second obesity
syndrome with very similar symptoms,
but this mutation, designated diabetes
(db), mapped to chromosome 4 (Hummel
et al., 1966). Mice homozygous for both of
these mutations demonstrated dramatic
early onset obesity, insulin resistance
(with varying severity of diabetes), infer-
tility, and a variety of other symptoms,
including hyperphagia (i.e., overeating)
and decreased locomotor activity. Of
interest, when the mutations were bred
onto strains with different genetic back-
grounds, the mice displayed substantial
phenotypic variation in several features,
including the presence of overt diabetes.
The Coleman lab carried out extensive
mouse breeding and phenotyping experi-
ments in an effort to understand how
the genetic background regulates these
metabolic phenotypes, an important but
still largely unresolved question.
Coleman’s most important observa-
tions, however, came from a series of
parabiosis experiments with the mutant
animals. When the subcutaneous tissues
of ob/ob mice were surgically connected
to that of either wild-type or db/db
animals, the ob/ob mice decreased
feeding and lost weight, and this effect
reversed when the union was ended.
Control mice were unaffected by the
union with ob/ob mice (Coleman, 1973).
In contrast, when normal mice were
parabiosed to db/db mice, control mice
stopped eating and lost substantial
amounts of weight, but the db/db mice
were unaffected. These results led Cole-
man to conclude correctly that ob/ob
mice lacked a satiety factor in their blood
stream that regulates feeding and weight.
Although both the control and db/dbmice
supplied this factor to the ob/obmice, the
db/db mice did so more robustly. Cole-
man, therefore, speculated that db/db
mice overproduced the circulating factorInc.to which they could not themselves
respond but which could be parabiotically
transferred to other animals to regulate
feeding and weight.
Aware of the experiments by Hervey
(1959), Coleman surmised that the hypo-
thalamus probably contained the center
that responds to the circulating factor.
As with conclusions from Hervey’s
studies, Coleman’s hypothesis proved to
be right on target. However, in the
absence of an identified circulating factor,
many physiologists and obesity investiga-
tors continued to reserve judgment about
the ultimate validity of the Coleman
hypothesis, just as they did with Hervey’s
conclusions. Nevertheless, some daring
investigators pursued this hypothesis
and sought to biochemically purify and
identify a factor from fat or other tissues
that regulates food intake. This approach,
although rational, did not succeed. For
a quarter of a century after Coleman’s
insightful experiments, researchers iden-
tified neither a specific factor, its site of
origin, nor its site of action. In fact, many
leaders of the field questioned whether
the efforts to find such a factor were
scientifically justified.
Friedman Finds the Genes
Enter Jeffrey Friedman, two decades after
Coleman’s work. Trained as a physician,
Friedman initially intended to become a
gastroenterologist. However, the emerg-
ing power of molecular genetics lured
him into a basic science laboratory to
study physiology and disease. Working
at The Rockefeller University, where he
obtained a PhD in the laboratory of James
Darnell Jr., Friedman became interested
in the genetics of body weight regulation
and decided to tackle the daunting task
of cloning the ob gene. Initially in collabo-
ration with other obesity researchers at
Rockefeller, including Rudolph Leibel,
Friedman methodically attacked this
goal and ultimately accomplished it. The
results led to insights that were nothing
short of breathtaking.
In a classic 1994 Nature paper, Fried-
man and colleagues described the ob
gene as a 4.5 kb transcript expressed
exclusively in adipose tissue and pre-
dicted to encode a secreted peptide
with 167 amino acids (Zhang et al.,
1994). Moreover, the transcript was dis-
rupted in both available ob alleles. Soon
after this initial paper, the Friedman group
and two others laboratories demon-
strated that treating ob/ob mice with the
recombinant peptide dramatically cor-
rected the animal’s obesity and hyper-
phagia (Halaas et al., 1995). Thus, the
peptide was named ‘‘leptin’’ from the
Greek root leptos for ‘‘thin.’’
Leptin was considerably more potent
when injected directly into the CNS than
into the blood stream, suggesting that
the primary target of leptin is in the CNS,
as Coleman predicted. Furthermore, lep-
tin failed to act in db/dbmice, which nicely
ruled out a nonspecific basis for the
weight loss and confirmed Coleman’s
hypothesis about the db/db mice lacking
the ability to detect the circulating satiety
factor. Thus, after almost a half a century
of searching, the biochemical cause of
obesity of the ob/ob mouse was finally
understood.
In work that soon followed, the Fried-
man laboratory and one other group found
that thedb locus encodes a family of leptin
receptors that are alternatively spliced
and members of the cytokine receptor
family (Lee et al., 1996). The db allele
altered only a single splice variant that,
unlike the other variants, is expressed
strongly in the hypothalamus. This variant
wasalso theonly leptin receptor predicted
to mediate signaling through the Jak/Stat
pathway. Not surprisingly, the Friedman
laboratory soon demonstrated that leptin
activates STAT3 in the hypothalamus
when it is systemically administered
(Vaisse et al., 1996). Furthermore, selec-
tively deleting this leptin receptor variant
from neurons recapitulates the major
features of the ob/ob syndrome.
Together, these findings demonstrated
the existence of a previously unknown
endocrine system through which the
status of energy stores in fat is communi-
cated by the hormone leptin to regulatory
centers in the brain. Absence of either the
ligand or the receptor caused severe and
similar obesity syndromes, revealing the
critical importance of this pathway and
its potential relevance to human disease.
Needless to say, this discovery trans-
formed the field of nutritional metabolism.
Leptin Research Today
Over the ensuing 15 years, researchers
have learned much more about the
biology and pathophysiology of leptin.Indeed, a PubMed search for ‘‘leptin’’
reveals more than 18,000 citations. The
major developments in this intensive
area of research can be grouped into
three areas: the physiologic role of leptin;
how leptin’s action is limited in human
obesity induced by diet or the environ-
ment; and the neural and peripheral
circuits upon which leptin acts.
Initially, leptin was thought of as amole-
cule produced by excess adipose tissue
to provide a negative feedback signal to
the brain to limit obesity by reducing
appetite and increasing energy expendi-
ture. However, new data and physiologic
thinking have substantially extended
this initial understanding. Clearly, leptin
reverses the syndrome of ob/ob mice,
and recombinant leptin has equally
dramatic effects on obese humans with
rare loss-of-function mutations in the lep-
tin gene (Farooqi et al., 1999). However,
disappointingly, both mice and humans
with more common forms of obesity typi-
cally have high levels of leptin, and more
importantly, their body weights respond
weakly or not at all to pharmacologic
supplementation of leptin (Heymsfield
et al., 1999). This suggests that ‘‘common
obesity’’ is a state of leptin resistance, as
opposed to leptin deficiency.
Of interest, obesity has long been
known to be a state of resistance to
insulin, the preeminent metabolic hor-
mone. Numerous studies have character-
ized the molecular mechanisms and
implications of insulin resistance associ-
ated with obesity. In obese patients,
raising already high levels of insulin even
further with exogenous doses typically
lowers blood glucose, revealing that
the resistance to insulin action on blood
glucose is relative, not absolute. In con-
trast, raising leptin levels even further in
the obese state has minimal effects on
body weight, suggesting that leptin resis-
tance to this important endpoint is almost
absolute. Consequently, the identification
of the molecular mechanisms underlying
leptin resistance is a central question to
address if we are to understand the path-
ophysiology of obesity as it occurs in
most people.
Studies in mice have identified two
likely mediators of leptin resistance. The
most well-characterized one, suppressor
of cytokine signaling 3 (SOCS3) (Bjørbaek
et al., 1998), is an intracellular inhibitor ofCell 1Jak/Stat signaling. Leptin acutely induces
expression of SOCS3 in target neurons,
and SOCS3 expression is also increased
in the hypothalamus of mice with diet-
induced obesity. Most decisively, disrupt-
ing the function of SOCS3 enhances
leptin signaling and limits obesity when
susceptible mice are placed on diets
that cause obesity (Howard et al., 2004).
A second candidate for an inhibitor of
leptin signaling is the tyrosine phospha-
tase PTP1b. As with SOCS3, disrupting
PTP1b protects against diet-induced
obesity (Zabolotny et al., 2002).
The most critical leptin signals are ex-
erted in the hypothalamus. The hypothal-
amus cannot be probed experimentally
in humans, and thus, our capacity to
assess the roles of SOCS3 and PTP1b in
human obesity is currently limited. Until
approaches are identified to counter
these inhibitory pathways, the existence
of leptin resistance in humans will limit
the therapeutic potential of leptin. Never-
theless, researchers are still actively
searching for obese individuals that
respond to leptin alone or in combination
with other therapies.
It seems likely that leptin will also have
therapeutic potential in disorders distinct
from obesity. Several states of ‘‘low lep-
tin’’ are associated neither with obesity
nor with mutations of the leptin gene.
For example, leanness and low body fat
can cause low levels of leptin in women
athletes, leading to amenorrhea and
anovulation, and leptin supplementation
may restore reproductive capacity in
these cases (Welt et al., 2004). In patients
with syndromes of ‘‘lipodystrophy,’’
multiple causes lead to a deficiency of
adipose tissue and thus leptin. Treatment
with leptin dramatically improves fatty
liver and insulin resistance in these
patients (Petersen et al., 2002).
Although a threshold of leptin action is
clearly required for preventing severe
obesity, this ‘‘anti-obesity’’ function para-
doxically may not be the singular or even
dominant physiologic role of leptin. Leptin
levels rise in obesity, consistent with
leptin’s function as a negative feedback
signal of energy stores. However, leptin
expression and circulating levels fall
quickly when normal mice and humans
are starved. May leptin be a signal for
adapting to starvation, as well as a signal
for resisting excessive weight gain?43, October 1, 2010 ª2010 Elsevier Inc. 11
In addition to increased hunger, starva-
tion induces a specific array of adaptive
endocrine and metabolic consequences,
including, most prominently, the suppres-
sion of reproductive capacity and de-
creased thyroid function. Importantly,
these changes are severely blunted
when leptin levels are kept constant by
exogenous supplementation during star-
vation of mice (Ahima et al., 1996). This
finding led to the hypothesis that falling
leptin is the dominant signal for initiating
a broad program of adaptation to starva-
tion. Indeed, the predicted impairments
of endocrine function during starvation
are also seen in ob/ob mice, such that
these mutant mice are actually experi-
encing the physiology of starvation
despite their severe obesity. We now
understand that these two faces of
leptin, mediating both the response to
starvation as levels fall and the response
to overfeeding as levels rise, represent
the full range of leptin biology. In 1998,
we hypothesized that leptin resistance
of weight regulatory pathways during
periods of energy excess provides an
evolutionary advantage; it limits the
capacity of leptin to keep an individual
excessively lean, which would cause
a more rapid demise during periods of
food deprivation.
The discovery of leptin has also
provided a powerful tool to explore the
central neural circuits that control energy
balance and related physiologies. A new
era in the neurobiology of energy balance
has been ushered in by the localization
of leptin receptors in specific regions of
the hypothalamus and the characteriza-
tion of the leptin’s ability to modulate
expression of neuropeptides involved
in regulation of appetite and body
weight. Researchers have demonstrated
that leptin reduces expression of several
neuropeptides that potently stimulate
feeding, such as Neuropeptide Y (NPY),
Agouti-related protein (AgRP), and
melanin concentrating hormone (MCH).
Conversely, leptin administration stimu-
lates expression of neuropeptides that
suppress feeding and weight. For
example, when neurons expressing pro-12 Cell 143, October 1, 2010 ª2010 Elsevieropiomelanocortin (POMC) are stimulated
by leptin, they produce the neuropeptide
aMSH, which stimulates central melano-
cortin 4 receptors on downstream
neurons. The consequence of this stimu-
lation is to suppress food intake and
body weight. The critical relevance of
this melanocortin circuit is evident not
only from its identity as a target of leptin
activation, but also from the fact that
loss of function of the cognate melano-
cortin 4 receptor is the most common
genetic cause of human obesity, account-
ing for 3%–5% of severe obesity in
humans. Leptin also has direct and indi-
rect actions in brain regions apart from
hypothalamus, and it is clear that the full
integrated circuitry of leptin action in brain
will require much additional research.
Conclusions
What lessons can we learn from the
discovery of leptin? First, indirect argu-
ments or data supporting the existence
of a physiologic system can be heuristi-
cally important and can serve as
strong stimuli to drive groundbreaking
research. Nevertheless, no matter how
compelling, such arguments are often
unconvincing to the scientific community
until the specific molecules underlying
the physiology are identified. Second,
the discovery of a powerful regulator of
appetite, energy balance, and body
weight can still leave many outstanding
questions about the mechanisms under-
lying disorders of body weight in humans.
This can frustrate efforts to translate the
discovery into an effective therapy for
common forms of obesity. Finally, we
should take note of the fact that both
The Rockefeller University and Howard
Hughes Medical Institute believed in Jeff
Friedman’s research project and sup-
ported his efforts during many years of
hard work when tangible results were
few and far between. The ability to make
such long-term bets on people and their
projects is difficult for funding agencies
and institutions. We should celebrate
the cases in which such confidence and
support is given, especially when the
researchers are successful and proveInc.that the outcome was well worth the
risk, as was the case here.
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